Forbes March 13, 2024
In November, the FDA released an announcement saying it was investigating reports of secondary cancers in people with blood cancers who were treated with CAR T cells.
The cellular therapy is made by extracting blood cells called T cells from a patient and then genetically engineering them to target a protein found on cancer cells. CAR T cells were first FDA-approved for the treatment of lymphoblastic leukemia in 2017 specifically for children and young adults who had exhausted all other treatment options. Since then, approvals have been granted for other types of blood cancer such as myeloma and lymphoma and trials in several types of solid tumors are underway.
Although the therapy has not been used on millions of people...
Today's Sponsors
Today's Sponsor